CLEC14A

Across TCGA pan-cancer cohorts, CLEC14A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLEC14A data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLEC14A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLEC14A expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where CLEC14A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.820	0.987	<.001	37	view →
PDAC	DFS	Quartile	All	0.251	0.502	.003	21	view →
UCEC	DFS	Median	All	0.800	1.000	.008	12	view →
HNSC	OS	Quartile	III,IV	1.000	0.815	.010	8	view →
CCRCC	DFS	Tertile	III,IV	0.629	0.327	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLEC14A–LUAD (DFS)

Open the LUAD breakdown →